Table 1.
Patient characteristics (n = 134)
| Age | Median (years) | 53 |
| Range | 10–78 | |
| Bone tumor | 29 (21.6%) | |
| Primary site | Humerus | 2 (1.5%) |
| Spine | 6 (4.5%) | |
| Femur | 16 (11.9%) | |
| Tibia | 3 (2.2%) | |
| Others | 2 (1.5%) | |
| Soft tissue tumor | 105 (78.4%) | |
| Primary site | Head and neck | 4 (3.0%) |
| Shoulder girdle | 3 (2.2%) | |
| Upper arm | 3 (2.2%) | |
| Forearm | 6 (4.5%) | |
| Other upper extremity | 5 (3.7%) | |
| Chest wall | 4 (3.0%) | |
| Buttock | 6 (4.5%) | |
| Retroperitoneum | 14 (10.4%) | |
| Visceral | 10 (7.5%) | |
| Thigh | 25 (18.7%) | |
| Leg | 9 (6.7%) | |
| Other lower extremity | 9 (6.7%) | |
| Others | 7 (5.2%) | |
| Histological subtype | ||
| Leiomyosarcoma | 38 (28.4%) | |
| Undifferentiated pleomorphic sarcoma | 20 (14.9%) | |
| Osteosarcoma | 17 (12.7%) | |
| Liposarcoma | 9 (6.7%) | |
| Synovial sarcoma | 7 (5.2%) | |
| Malignant peripheral nerve sheath tumor | 7 (5.2%) | |
| Angiosarcoma | 4 (3.0%) | |
| Ewing sarcoma | 4 (3.0%) | |
| Epithelioid sarcoma | 4 (3.0%) | |
| Rhabdomyosarcoma | 3 (2.2%) | |
| Others | 21 (15.7%) | |
| Presentation status | ||
| Localized | 9 (6.7%) | |
| Metastatic or locally advanced | 125 (93.3%) | |
| Prior chemotherapy regimen | ||
| DOX+IFO | 38 (28.4%) | |
| DOX alone | 21 (15.7%) | |
| IFO alone | 18 (13.4%) | |
| IFO+VP16 | 12 (9.0%) | |
| IFO+CDBCA+VP16 | 11 (8.2%) | |
| DOX+CDDP | 6 (4.5%) | |
| None | 32 (23.9%) | |
| Prior radiation | 45 (33.6%) | |